



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	☒ HIV-1 LAV infected Jurkat E6 Cells (J1.1)
Catalog Number:	1340
Lot Number:	080012
Release Category:	C
Provided:	1.2 x 10 ⁷ cells/mL. Viability is 92%.
Cell Type:	Derived from Jurkat. Morphology is mature lymphocytic.
Propagation Medium:	RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 90%; fetal bovine serum, 10%.
Freeze Medium:	Propagation medium, 92.5%; DMSO, 7.5%.
Growth Characteristics:	When thawing, dilute the cells with 37°C medium dropwise, wash out the DMSO, and seed the initial culture at 1 x 10 ⁶ cells/ml. Passage the cells every three days to give a concentration of 1 x 10 ⁶ cells/ml. Cells grow in single cell suspension. Doubling time is 24 hours.
Sterility:	Negative for mycoplasma, bacteria and fungi.
Special Characteristics:	Latently HIV infected cell line cloned by limiting dilution from HIV-infected Jurkat cells. HIV capable of being induced with PMA or TNF. <u>Time in culture after cryorecovery of J1 Cells</u>
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Thomas M. Folks.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References: Perez VL, Rowe T, Justement JS, Butera ST, June CH, Folks TM. An HIV-1-infected T cell clone defective in IL-2 production and Ca²⁺ mobilization after CD3 stimulation. *J Immunol* **147**:3145-3148, 1991.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 LAV infected Jurkat E6 Cells (J1.1) from Dr. Thomas Folks." Also include the reference cited above in any publications.

Scientists at for-profit institutions or who intend commercial use of this reagent must contact Tom O'Toole at email address teo1@cdc.gov and specify in the email the name of the reagent, and a description of the intended use of the reagent.

Last Updated September 01, 2016

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.